MOLECULAR PARTNERS AG

MOLN Nasdaq CIK: 0001745114

Company Information

Industry Biological Products, (No Diagnostic Substances)
SIC Code 2836
Entity Type other
SEC Category Non-accelerated filerEmerging growth company
State of Incorporation Switzerland
Business Address WAGISTRASSE 14, Schlieren-Zurich, V8, 8952
Mailing Address WAGISTRASSE 14, Schlieren-Zurich, V8, 8952
Phone 41 44 755 77 00
Fiscal Year End 1231
EIN 000000000

Recent SEC Filings

Form Type Date Filed Document
6-K Foreign company current report March 30, 2026 View on SEC
6-K Foreign company current report March 13, 2026 View on SEC
6-K Foreign company current report March 12, 2026 View on SEC
20-F Foreign company annual report March 12, 2026 View on SEC
6-K Foreign company current report February 2, 2026 View on SEC
6-K Foreign company current report January 12, 2026 View on SEC
6-K Foreign company current report December 8, 2025 View on SEC
6-K Foreign company current report November 12, 2025 View on SEC
6-K Foreign company current report October 30, 2025 View on SEC
6-K Foreign company current report August 25, 2025 View on SEC

Annual Reports

20-F March 12, 2026
  • MOLECULAR PARTNERS AG leverages its proprietary DARPIN® technology for novel therapies, offering advantages over traditional antibodies.
  • The company maintains significant co-development and license agreements with Novartis AG (focusing on DARPIN Conjugated Radioligand Therapies) and OranoMed.
View Analysis

Related Companies

Companies in the same industry (SIC: 2836)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.